Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00121355 · ClinicalTrials.gov registry record · Phase 4

Novofine Autocover Safety Needle Versus BD Safety Glide

A Phase 4 study of Diabetes and Delivery Systems, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 4
Development phase
83
Enrollment target
1
Study location

NCT00121355 is a Phase 4 study of Diabetes and Delivery Systems that has completed, run by Novo Nordisk A/S. The registered enrollment target is 83 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00121355, a Phase 4 study of Diabetes and Delivery Systems, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 4
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.

Interventions

  • DEVICE safety glide
  • DEVICE autocover needle

Study Locations (1)

New Jersey

  • Novo Nordisk Investigational Site - Plainsboro

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2005-07
Est. Completion 2006-06
Phase Phase 4

Sponsor

Novo Nordisk A/S

431 total trials

What the Registry Record Tells You About NCT00121355

The ClinicalTrials.gov registry entry for NCT00121355 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which safety glide is the first listed.

NCT00121355 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00121355 about?

NCT00121355 is a clinical study titled "Novofine Autocover Safety Needle Versus BD Safety Glide". This trial is conducted in the United States of America (USA). The aim of this trial is to examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether thes...

What is the current status of trial NCT00121355?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2005-07. Estimated completion is 2006-06.

What conditions does trial NCT00121355 study?

This clinical trial studies the following conditions: Diabetes, Delivery Systems, Healthcare Professionals.

What interventions are being tested in trial NCT00121355?

The interventions under investigation include: safety glide (DEVICE), autocover needle (DEVICE).

Who is sponsoring clinical trial NCT00121355?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00121355 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.